- Home
- OABI vs FHTX Comparison
OABI vs FHTX Comparison
Compare OABI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OABI | FHTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.3M | 266.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OABI | FHTX |
|---|---|---|
| Price | $4.39 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.50 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.5M | 392.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.56 | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | $18,666,000.00 | ★ $30,909,000.00 |
| Revenue This Year | $52.42 | $8.89 |
| Revenue Next Year | $64.69 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.32 | $3.27 |
| 52 Week High | $5.43 | $7.61 |
Technical Indicators
Market Signals| Indicator | OABI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 25.61 |
| Support Level | $3.89 | $3.57 |
| Resistance Level | $5.43 | $5.87 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 28.90 | 2.11 |
Price Performance
Historical ComparisonAbout OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.